nach oben

Current Bladder Dysfunction Reports

Erschienen in:

28.04.2018 | Overactive Bladder (U Lee and S Adelstein, Section Editors)

Trends in Utilization of Third-Line Therapies for Non-neurogenic Overactive Bladder: Sacral Neuromodulation, Peripheral Tibial Nerve Stimulation, and Intradetrusor OnabotulinumtoxinA

verfasst von: Anna C. Kirby, Elizabeth S. Kellogg

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To report on current and emerging trends in the use of third-line therapies for non-neurogenic overactive bladder (OAB).

Recent findings

The use of third-line therapies for OAB has been steadily increasing, but it appears that only a small percentage of OAB patients receive them. Recent research has found an increased risk of dementia associated with cumulative use of anticholinergic medications, including OAB antimuscarinic medications. Cost-effective analyses suggest that these third-line therapies may be worth considering prior to medications.

Summary

Research and efforts to improve adherence to current OAB guidelines are needed to increase their use by patients with refractory OAB. Whether or not the therapies we presently consider third line should actually be second line for some of our patients remains to be determined.

Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20.PubMed

•• Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological A. Society of Urodynamics FPM. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80. The most up to date guidelines regarding OAB diagnosis and treatment. CrossRefPubMed

Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–82.CrossRefPubMed

Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol. 2014;191(4):1003–8.CrossRefPubMed

Peters KM, Killinger KA, Boguslawski BM, Boura JA. Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn. 2010;29(7):1267–71.CrossRefPubMed

Elterman DS, Chughtai B, Vertosick E, Thomas D, Eastham J, Sandhu J. Trends and clinical practice patterns of sacral neuromodulation for overactive bladder. Female Pelvic Med Reconstr Surg 2017, 1.

Laudano MA, Seklehner S, Sandhu J, Reynolds WS, Garrett KA, Milsom JW, et al. Disparities in the use of sacral neuromodulation among medicare beneficiaries. J Urol. 2015;194(2):449–53.CrossRefPubMed

Withington J, Hirji S, Sahai A. The changing face of urinary continence surgery in England: a perspective from the hospital episode statistics database. BJU Int. 2014;114(2):268–77.CrossRefPubMed

Suskind AM, Dunn RL, Kaufman SR, DeLancey JO, Clemens JQ, Stoffel JT, et al. Understanding the dissemination of sacral neuromodulation. Surg Innov. 2013;20(6):625–30.CrossRefPubMedPubMedCentral

10.

Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol. 2013;189(6):2194–201.CrossRefPubMed

11.

Wolff EM PS, Odem-Davis K, Kirby AC. Modern practice patterns in women treated for non-neurogenic overactive bladder: how quickly do patients progress to third-line therapy. Female Pelvic Med Reconstr Surg. 2017;23(5S Abstracts).

12.

Moskowitz D, Adelstein SA, Lucioni A, Lee UJ, Kobashi KC. Use of third line therapy of overactive bladder in a practice with multiple subspecialty providers: are we doing enough? J Urol. 2017;197:e528–9.CrossRef

13.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2017;197(2S):S216–S23.CrossRefPubMed

14.

Minassian VA, Yan X, Lichtenfeld MJ, Sun H, Stewart WF. The iceberg of health care utilization in women with urinary incontinence. Int Urogynecol J. 2012;23(8):1087–93.CrossRefPubMedPubMedCentral

15.

Goldman HB, Anger JT, Esinduy CB, Zou KH, Russell D, Luo X, et al. Real-world patterns of care for the overactive bladder syndrome in the United States. Urology. 2016;87:64–9.CrossRefPubMed

16.

Brostrom S, Hallas J. Persistence of antimuscarinic drug use. Eur J Clin Pharmacol. 2009;65(3):309–14.CrossRefPubMed

17.

Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California medicaid program. Value Health. 2005;8(4):495–505.CrossRefPubMed

18.

Firoozi F, Gill B, Ingber MS, Moore CK, Rackley RR, Goldman HB, et al. Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged. J Urol. 2013;190(2):594–7.CrossRefPubMed

19.

Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72(3):389–99.CrossRefPubMed

20.

•• Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316(13):1366–74. The largest RCT comparing sacral neuromodulation with onabotultinumtoxinA performed at multiple centers by the Pelvic FLoor Disorders Network. CrossRefPubMedPubMedCentral

21.

•• Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7. This study changes how we evaluate side effects of anticholinergic medications for our patients. Whereas previously we considered side effects to be potentially bothersome but reversible with cessation of antimuscarinic medications, we now have to counsel our patients regfarding the potential increased use of dementia with cumulative use. CrossRefPubMedPubMedCentral

22.

Committee AUSG. AUGS Consensus Statement: Association of anticholinergic medication use and cognition in women with overactive bladder. Female Pelvic Med Reconstr Surg. 2017;23(3):177–8.

23.

• Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803–13. The largest RCT comparing antimuscarinic medications to onabotulinumtoxinA for OAB, performed at multiple sites by the Pelvic Floor Disorders Network. CrossRefPubMedPubMedCentral

24.

•• Carter-Brooks CM, Shepherd J. A cost-effectiveness analysis of botox botulinum-A toxin as first-line treatment for overactive bladder. Female Pelvic Med Reconstr Surg. 2017;23(5S Abstracts):S17–75. AUGS abstract suggesting onabotulinumtoxinA might be cost-effective as a treatment for any patients with OAB, not just patients with refractory OAB.

25.

Hassouna MM, Sadri H. Economic evaluation of sacral neuromodulation in overactive bladder: a Canadian perspective. Can Urol Assoc J. 2015;9(7–8):242–7.CrossRefPubMedPubMedCentral

26.

Autiero SW, Hallas N, Betts CD, Ockrim JL. The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. BJU Int. 2015;116(6):945–54.CrossRefPubMed

27.

Bertapelle MP, Vottero M, Popolo GD, Mencarini M, Ostardo E, Spinelli M, et al. Sacral neuromodulation and botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. World J Urol. 2015;33(8):1109–17.CrossRefPubMed

28.

Martinson M, MacDiarmid S, Black E. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. J Urol. 2013;189(1):210–6.CrossRefPubMed

Titel: Trends in Utilization of Third-Line Therapies for Non-neurogenic Overactive Bladder: Sacral Neuromodulation, Peripheral Tibial Nerve Stimulation, and Intradetrusor OnabotulinumtoxinA
verfasst von: Anna C. Kirby
Elizabeth S. Kellogg
Publikationsdatum: 28.04.2018
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 2/2018
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-018-0462-7

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Trends in Utilization of Third-Line Therapies for Non-neurogenic Overactive Bladder: Sacral Neuromodulation, Peripheral Tibial Nerve Stimulation, and Intradetrusor OnabotulinumtoxinA

Abstract

Purpose of Review

Recent findings

Summary

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Purpose of Review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Prostate Artery Embolization: Current Status 2018

Insight Into the Central Control of Overactive Bladder Symptoms by Functional Brain Imaging

Urologic Applications of the Microbiota in Multiple Sclerosis

Stress Urinary Incontinence in Women with Neurogenic Lower Urinary Tract Dysfunction

Non-invasive Testing and Its Role in Diagnosis and Management of Children With Voiding Dysfunction

Management of Overactive Bladder in Children

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie